Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362997 | 0.86 | DPP4 (0.41) | KEAP1NFE2L2FFAR1KMT2AGPBAR1 | |
| SCHEMBL363436 | 0.83 | KMT2A (0.47) | KEAP1NFE2L2FFAR1MEN1KMT2A | |
| SCHEMBL363622 | 0.83 | HPGD (0.40) | KEAP1NFE2L2ALDH1A1MAPTMEN1 | |
| SCHEMBL1390233 | 0.81 | GPBAR1 (0.40) | KEAP1NFE2L2ALDH1A1MAPTFFAR1 | |
| SCHEMBL363953 | 0.80 | GPBAR1 (0.46) | ALDH1A1MAPTMEN1KMT2ANQO1 | |
| SCHEMBL1979497 | 0.80 | FFAR1 (0.51) | ALDH1A1FFAR1MEN1KMT2A | |
| SCHEMBL1390346 | 0.80 | GPBAR1 (0.56) | MEN1KMT2AGPBAR1CTSA | |
| SCHEMBL370930 | 0.79 | EPHX2 (0.45) | KMT2A | |
| SCHEMBL371141 | 0.79 | GPBAR1 (0.37) | KEAP1NFE2L2ALDH1A1MAPTMEN1 | |
| SCHEMBL371142 | 0.78 | MGAM (0.41) | KEAP1NFE2L2MEN1KMT2ANQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | KEAP1 1693/4885NFE2L2 488/4885ALDH1A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.